dc.date.accessioned | 2020-06-24T18:33:53Z | |
dc.date.available | 2020-06-24T18:33:53Z | |
dc.date.created | 2019-06-14T10:50:31Z | |
dc.date.issued | 2019 | |
dc.identifier.citation | Josefsson, Sarah Elisabet Beiske, Klaus Blaker, Yngvild Nuvin Førsund, Mette S Holte, Harald Østenstad, Bjørn Kimby, Eva Köksal, Hakan Wälchli, Sébastien Bai, Baoyan Smeland, Erlend B Levy, Ronald Kolstad, Arne Huse, Kanutte Myklebust, June . TIGIT and PD-1 mark intratumoral T cells with reduced effector function in B-cell non-Hodgkin lymphoma. Cancer immunology research. 2019, 7(3), 355-362 | |
dc.identifier.uri | http://hdl.handle.net/10852/77197 | |
dc.description.abstract | Checkpoint blockade can reverse T-cell exhaustion and promote antitumor responses. Although blocking the PD-1 pathway has been successful in Hodgkin lymphoma, response rates have been modest in B-cell non-Hodgkin lymphoma (NHL). Coblockade of checkpoint receptors may therefore be necessary to optimize antitumor T-cell responses. Here, characterization of coinhibitory receptor expression in intratumoral T cells from different NHL types identified TIGIT and PD-1 as frequently expressed coinhibitory receptors. Tumors from NHL patients were enriched in CD8+ and CD4+ T effector memory cells that displayed high coexpression of TIGIT and PD-1, and coexpression of these checkpoint receptors identified T cells with reduced production of IFNγ, TNFα, and IL2. The suppressed cytokine production could be improved upon in vitro culture in the absence of ligands. Whereas PD-L1 was expressed by macrophages, the TIGIT ligands CD155 and CD112 were expressed by lymphoma cells in 39% and 50% of DLBCL cases and in some mantle cell lymphoma cases, as well as by endothelium and follicular dendritic cells in all NHLs investigated. Collectively, our results show that TIGIT and PD-1 mark dysfunctional T cells and suggest that TIGIT and PD-1 coblockade should be further explored to elicit potent antitumor responses in patients with NHL. | |
dc.language | EN | |
dc.publisher | American Association for Cancer Research | |
dc.title | TIGIT and PD-1 mark intratumoral T cells with reduced effector function in B-cell non-Hodgkin lymphoma | |
dc.type | Journal article | |
dc.creator.author | Josefsson, Sarah Elisabet | |
dc.creator.author | Beiske, Klaus | |
dc.creator.author | Blaker, Yngvild Nuvin | |
dc.creator.author | Førsund, Mette S | |
dc.creator.author | Holte, Harald | |
dc.creator.author | Østenstad, Bjørn | |
dc.creator.author | Kimby, Eva | |
dc.creator.author | Köksal, Hakan | |
dc.creator.author | Wälchli, Sébastien | |
dc.creator.author | Bai, Baoyan | |
dc.creator.author | Smeland, Erlend B | |
dc.creator.author | Levy, Ronald | |
dc.creator.author | Kolstad, Arne | |
dc.creator.author | Huse, Kanutte | |
dc.creator.author | Myklebust, June | |
cristin.unitcode | 185,53,18,75 | |
cristin.unitname | K.G. Jebsen senter for B-cellekreft - del UiO | |
cristin.ispublished | true | |
cristin.fulltext | postprint | |
cristin.qualitycode | 1 | |
dc.identifier.cristin | 1704897 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Cancer immunology research&rft.volume=7&rft.spage=355&rft.date=2019 | |
dc.identifier.jtitle | Cancer immunology research | |
dc.identifier.volume | 7 | |
dc.identifier.issue | 3 | |
dc.identifier.startpage | 355 | |
dc.identifier.endpage | 362 | |
dc.identifier.doi | https://doi.org/10.1158/2326-6066.CIR-18-0351 | |
dc.identifier.urn | URN:NBN:no-80314 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 2326-6066 | |
dc.identifier.fulltext | Fulltext https://www.duo.uio.no/bitstream/handle/10852/77197/2/Josefsson%2Bet%2Bal_Cristin-post%2B1704897_Cancer%2BImmunol%2BRes_merged.pdf | |
dc.type.version | AcceptedVersion | |
dc.relation.project | NFR/230817 | |